Gloria E Marino
Overview
Explore the profile of Gloria E Marino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
285
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fane M, Chhabra Y, Alicea G, Maranto D, Douglass S, Webster M, et al.
Nature
. 2025 Jan;
638(8051):E31.
PMID: 39890900
No abstract available.
2.
Fane M, Ecker B, Kaur A, Marino G, Alicea G, Douglass S, et al.
Clin Cancer Res
. 2023 May;
29(10):2012.
PMID: 37183634
No abstract available.
3.
Marino G, Weeraratna A
Aging Cancer
. 2022 Jun;
1(1-4):19-29.
PMID: 35694033
People over 55 years old represent the majority of cancer patients and suffer from increased metastatic burden compared to the younger patient population. As the aging population increases globally, it...
4.
Fane M, Chhabra Y, Alicea G, Maranto D, Douglass S, Webster M, et al.
Nature
. 2022 Jun;
606(7913):396-405.
PMID: 35650435
Disseminated cancer cells from primary tumours can seed in distal tissues, but may take several years to form overt metastases, a phenomenon that is termed tumour dormancy. Despite its importance...
5.
Fane M, Ecker B, Kaur A, Marino G, Alicea G, Douglass S, et al.
Clin Cancer Res
. 2020 Oct;
26(21):5709-5719.
PMID: 33097493
Purpose: Angiogenesis is thought to be critical for tumor metastasis. However, inhibiting angiogenesis using antibodies such as bevacizumab (Avastin), has had little impact on melanoma patient survival. We have demonstrated...
6.
Webster M, Fane M, Alicea G, Basu S, Kossenkov A, Marino G, et al.
Mol Cell
. 2020 Feb;
77(3):681.
PMID: 32032511
No abstract available.
7.
Webster M, Fane M, Alicea G, Basu S, Kossenkov A, Marino G, et al.
Mol Cell
. 2019 Dec;
77(3):633-644.e5.
PMID: 31836388
Metastatic melanoma is an aggressive disease, despite recent improvements in therapy. Eradicating all melanoma cells even in drug-sensitive tumors is unsuccessful in patients because a subset of cells can transition...
8.
Rivera-Reyes A, Ye S, Marino G, Egolf S, Ciotti G, Chor S, et al.
Cell Death Dis
. 2018 Nov;
9(11):1108.
PMID: 30382078
Terminal differentiation opposes proliferation in the vast majority of tissue types. As a result, loss of lineage differentiation is a hallmark of aggressive cancers, including soft tissue sarcomas (STS). Consistent...
9.
Ecker B, Kaur A, Douglass S, Webster M, Almeida F, Marino G, et al.
Cancer Discov
. 2018 Oct;
9(1):82-95.
PMID: 30279172
Older patients with melanoma have lower rates of sentinel lymph node (LN) metastases yet paradoxically have inferior survival. Patient age correlated with an inability to retain Technetium radiotracer during sentinel...
10.
Ye S, Lawlor M, Rivera-Reyes A, Egolf S, Chor S, Pak K, et al.
Cancer Res
. 2018 Mar;
78(10):2705-2720.
PMID: 29490948
To date, no consistent oncogenic driver mutations have been identified in most adult soft tissue sarcomas; these tumors are thus generally insensitive to existing targeted therapies. Here we investigated alternate...